GSK has partnered with CureVac to develop the mRNA vaccine in more than $1 billion.

Guide: Co-research, development, manufacture, and commercialization of up to as many vaccines and monoclonal antibodies for infectious disease pathogensGlaxoSmithKline and Co., Inchave jointly announced a strategic cooperation agreement to jointly research, develop, manufacture and commercialize up to as many vaccines and monoclonal antibodies for infectious disease pathogensTechnology is a cutting-edge platform for the development of new vaccines and new drug development, which potentially expands the scope of disease treatment and prevention and is expected to significantly accelerate the development and production of new therapiesIn the human body is responsible for protein synthesis and carrytheing the genetic code needed for cell synthesis and expression of proteinsApplying technology to vaccine development and therapy enables the body's own cells to produce specific proteins or antigens that can fight disease through the human immune systemThe technology platform has demonstrated its potential in the development and production of vaccines and therapeutic preparations And its self-developed platform is designed to optimize product characteristics based on three core pillar technologies: protein design, optimization and deliveryUsers can customize the platform to induce varying degrees of immune response to selected specific protein antigens, potentially providing an effective preventive vaccine against infectious diseases such as rabies and immunotherapy for cancer patientsThe platform's core idea map source: The official website will invest billions of pounds (about $100 million) in equity investments equivalent to the latter's shares under the terms of the agreement and make an advance payment of 100 million pounds ($100 million)Given that the commercial standard production facility under construction is being certified in Germany, a one-time fee of 10,000 pounds (approximately US$10,000) will also be paid for the reservation of manufacturing capacityIt will also be eligible for up to 100 million pounds ($a billion) in payments for development and regulatory milestones, as well as royalties graded by product salesPreclinical research and development and phase clinical trials that will be responsible for these projects will take over the follow-up research and development and commercialization work and will be responsible for the manufacturing of candidate products, including post-marketing production, and the right to commercialize all candidate products in designated countries